Mounjaro (Tirzepatide) Description:Mounjaro (tirzepatide) is an FDA-approved injectable prescription medication used to improve blood sugar control in adults with type 2 diabetes. It belongs to a new class of medications that work as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating both receptors, Mounjaro helps regulate blood sugar, slow digestion, and decrease appetite. Clinical studies have also demonstrated its effectiveness in supporting weight reduction. Key Benefits: Improves glycemic control: Enhances insulin secretion and lowers blood glucose levels in adults with type 2 diabetes. Supports weight management: Reduces appetite and caloric intake, leading to meaningful weight loss for many patients. Dual-action mechanism: Works on both GIP and GLP-1 pathways for improved metabolic regulation. Convenient once-weekly injection: Designed to support long-term adherence and results. Important Note:Mounjaro should only be prescribed and monitored by a licensed healthcare provider. It may not be suitable for everyone and can have potential side effects or contraindications. TERMS & CONDITIONS Offers available for purchase from September 1, 2025 to September 30, 2025.Offers valid for 3 months after purchase. Maximum purchase of 2 offers per client and cannot be combined with other offers. Limited quantities available while supplies last. A total of 100 services are available. All sales are final; no returns or service transfers are accepted. All these weight-control injectables are administered up to a maximum of 0.50ml.